Lakefront Biotherapeutics (GLPGF) Other Accumulated Expenses (2014 - 2020)

Lakefront Biotherapeutics (GLPGF) has reported Other Accumulated Expenses for 4 consecutive years, with -$391.4 million the latest figure, recorded in Q2 2020.

• On a quarterly basis, Other Accumulated Expenses fell 69.01% year-over-year to -$391.4 million in Q2 2020; TTM through Jun 2020 was -$391.4 million, a 69.01% decrease from a year earlier, with the FY2019 full-year figure at -$581.8 million, down 40.55% from the prior year.
• Other Accumulated Expenses was -$391.4 million for Q2 2020 at Lakefront Biotherapeutics, up from -$581.8 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at -$94.4 million in Q1 2018 and troughed at -$581.8 million in Q4 2019.
• A 3-year average of -$303.4 million and a median of -$311.5 million in 2020 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses decreased 13.32% in 2019 and tumbled 69.01% in 2020, its largest moves.
• Over 3 years, Other Accumulated Expenses stood at -$413.9 million in 2018, then plunged by 40.55% to -$581.8 million in 2019, then jumped by 32.72% to -$391.4 million in 2020.
• The last three Other Accumulated Expenses figures came in at -$391.4 million (Q2 2020), -$581.8 million (Q4 2019), and -$231.6 million (Q2 2019), per Business Quant data.